Medical oncologist
Gastrointestinal cancers, treated with precision and with time to talk.
Colon and rectum, pancreas, stomach, esophagus, liver and bile ducts. Every decision is explained clearly, grounded in current science and made together with you.
CRM-SP 220000 · CRM-MG 86471 · RQE 71154
About
My parents are doctors, as is much of my family. Whenever I was asked what I would be if I could be anything in the world, the answer was always the same: a doctor.
I learned early on to hold myself to a rigorous work ethic, which has guided me throughout my life. I studied at the Federal University of Minas Gerais, one of the best public universities in Brazil. I then trained in internal medicine at Santa Casa de São Paulo, which has one of the highest patient volumes in Latin America. There, I learned internal medicine in practice, at the bedside. I came to understand that we all carry pain and fear, no matter where we come from. I held the hands of patients and their families whenever they needed it. I delivered more sad news than I can count, and just as much good news. And I learned a valuable lesson: to be present, whatever the circumstances.
Why oncology?
This is the first question I get when I tell people what I do. It’s natural. When I explain, I start with the rational reasons: the range of settings, my love for the subject, innovation…
On the personal side, an anecdotal example: a much-loved grandfather diagnosed with lung cancer. Like many families, I wished we had done more and better, but I also had my first oncology lesson: the inevitability of finitude.
But I dare say it is actually another part of the profession that moves me. Deep down, every oncologist is an optimist or, at least, a hopeful realist, to paraphrase the Brazilian writer Ariano Suassuna. Today I see a profession that has taught me more about winning than about losing.
Having cancer does not have to be a burden. We can face it together.
Throughout my training, I was lucky. At Einstein, I took my first steps in my career alongside kind and brilliant people. I had great supervisors who became mentors, and great mentors who became friends. All of them essential to the oncologist I am.
Today, I focus on gastrointestinal cancers and tumor-agnostic therapies, which treat cancer according to the tumor’s genetic alteration rather than the organ where it began. In my research, I work on access to innovation, cancer prevention and the rational use of therapies.
My goal is for every patient to have access to the most current cancer treatment, wherever they are, always with empathetic, comprehensive care. I will be by your side at every step.
I see patients in Portuguese, English and Spanish.
Education
- 2015–2021Federal University of Minas GeraisDoctor of Medicine
- 2021–2023Santa Casa de São PauloInternal Medicine residency · chief resident
- 2023–2026Hospital Israelita Albert EinsteinMedical Oncology residency
International experience
- 2024University of PisaGastrointestinal Oncology observership · Italy
- 2025AIOM and ASCO Clinical Research CourseRome, Italy
- 2025City of Hope Comprehensive Cancer CenterMedical Oncology observership, gastrointestinal cancers · California, USA
Areas of practice
Gastrointestinal cancers
Colon and rectum
Colorectal cancer, from diagnosis to follow-up after treatment.
Pancreas
Treatment at every stage, including the newest therapies targeting RAS alterations.
Stomach and esophagus
Treatment planning before and after surgery, with chemotherapy and immunotherapy when indicated.
Bile ducts
Cholangiocarcinoma and gallbladder cancer, with genomic testing of the tumor to guide options.
Liver
Hepatocellular carcinoma, decided jointly with surgery, hepatology and interventional radiology.
Precision oncology
Liquid biopsy and genomic sequencing to match treatment to the tumor’s profile.
The consultation
How it works
First contact
You speak directly with the team to ask practical questions about the visit.
Before the visit
Gather your test results, biopsy reports, medical summaries and a list of current medications. If possible, bring the scan images too, not only the reports.
An unhurried consultation
We review your full history and every test. A family member or trusted person is welcome. No question goes unanswered.
A clear plan, in writing
You leave knowing the diagnosis, the treatment options, what to expect from each and the next steps, all written down.
Close follow-up
During treatment, you have a direct line to me for questions and concerns.
Practical guide
Your first visit with an oncologist
What you need to know, from A to Z.
Read the guideFor patients and families
Articles
Oncology, explained without jargon.
From my Substack
See allA second opinion in oncology: when it makes sense and how to prepare
Which documents to bring, what to ask and how to talk about it with your current doctor.
Read Practical guide · November 2026Chemotherapy: what to expect and how to look after yourself
How a cycle works, the most common side effects and what helps, when to call the team right away, and everyday care.
Read Myths and facts · November 2026Does sugar feed cancer?
Why cutting out all sugar does not "starve the tumor", where sugar really matters and what to do in practice.
Read Practical guide · November 2026I’ve finished treatment. What now?
The emptiness many people feel when treatment ends, what follow-up looks like, effects that may appear over time, the fear of the cancer coming back and what helps you live well.
Read Prevention · November 2026Obesity and cancer: what weight has to do with the disease
Why excess weight raises the risk, how it affects treatment and what really helps, without guilt or miracle diets.
Read Practical guide · November 2026Spirituality during cancer: care that is yours too
What spirituality is, why it matters during treatment, how to talk about it with your team and what can help, with or without religion.
Read Practical guide · November 2026Vaccines during cancer treatment: which ones, when and where
Which vaccines are safe, which should wait, the best timing, vaccinating your family and how to use Brazil’s CRIE centers.
Read Practical guide · November 2026Exercise during and after cancer: every movement counts
Why moving helps, how much to do, the talk test to get the intensity right, special precautions and when to stop.
Read Practical guide · November 2026Eating during cancer treatment: what really helps
Why keeping weight and muscle matters, when weight loss is a concern, tips for nausea, mouth sores and other symptoms, and the myths that get in the way.
Read Global oncology · November 2026Where you live changes your chance of beating cancer
A portrait of cancer worldwide and in Brazil: the inequalities, the barriers that remain and the paths to bring progress to everyone.
Read Practical guide · November 2026Your first visit with an oncologist: what you need to know
From A to Z: what cancer is, when to see an oncologist, what staging (TNM) means, what to bring and the questions worth asking.
Read Myths and facts · November 2026Does a cure for cancer already exist?
How a cancer is born, why each one has a different treatment, which are already curable and why a "hidden cure" makes no sense.
Read Prevention · November 2026Cancer in the family: when genes raise the risk
BRCA and Angelina Jolie’s story, Lynch syndrome, Li-Fraumeni and its history in Brazil, and when to get genetic testing.
ReadFrom my research
My studies, explained for you.
KRAS-targeted drugs in pancreatic cancer: what the first trials show
We pooled five early trials with 301 patients: about one in four had major tumor shrinkage.
Read Bile ducts · WJCO, 2025Tumor DNA in blood and bile: a shortcut to understanding bile duct cancer
How to study the tumor’s genetic profile without a new biopsy, and why bile is surprising.
Read Stomach · WJCO, 2025Immunotherapy around stomach cancer surgery: what we know and what is still open
What the large trials showed and who seems to benefit most from immunotherapy.
Read Access to treatment · JAMA Network Open, 2025When the drug arrives through the courts: access to pembrolizumab in Brazil
We analyzed 1,288 lawsuits. One third were denied, almost always because of incomplete paperwork.
Read Bile ducts · TGH, 202645 years of bile duct cancer research: what has changed and what is still missing
427 trials and 23,000 patients: precision medicine has begun to change a story that moved slowly.
Read Precision medicine · Biomedicines, 2026More mutations, better response to immunotherapy?
What we saw in 133 patients with tumors with a very high mutational burden.
ReadResearch
Scientific publications
23 publications · 96 citations · h-index 5 Web of Science, November 2026
- 2026
Landscape of clinical trials and impact of precision medicine in biliary tract cancers in the last 45 years: a systematic review and meta-analysis of biomarker-driven trials
Translational Gastroenterology and Hepatology. DOI 10.21037/tgh-2026-0015
- 2026
Very high vs. high tumor mutational burden across tumors: real-world associations with MSI, pathway features, and immunotherapy outcomes
Biomedicines. DOI 10.3390/biomedicines14030593
- 2026
Efficacy and safety signals from early-phase studies of KRAS inhibition in pancreatic cancer First author
Teixeira MF, et al. Scientific Reports. DOI 10.1038/s41598-026-40757-3
- 2026
Utility of circulating tumor DNA-based liquid biopsies in patients with cancer receiving immunotherapy First author
Teixeira MF, Fahmy N, Kasi PM. Surgical Oncology Clinics.
- 2026
Clinico-genomic characterization of TP53/CDKN2A co-alteration and its prognostic value in biliary tract cancer
Pirozzi A, Shibuki T, Teixeira MF, et al. Journal of Clinical Oncology. DOI 10.1200/JCO.2026.44.2_suppl.593
- 2026
Prognostic role of PIK3CA and co-alterations in advanced biliary tract cancer: a multicenter retrospective analysis
Abidoye O, Kosiorek HE, Shibuki T, … Teixeira MF, et al. Journal of Clinical Oncology. DOI 10.1200/JCO.2026.44.2_suppl.599
- 2026
Olaparib response in a patient with platinum-refractory germ cell tumor harboring a somatic BRIP1 mutation
Gismondi CBL, Agarwal R, Teixeira MF, Chehrazi-Raffle A. JCO Precision Oncology. DOI 10.1200/PO-25-00768
- 2025
Access barriers to pembrolizumab in Brazil
Uson Junior PLS, Rocioli Jr UD, Teixeira MF, et al. JAMA Network Open, 8(8):e2528585. DOI 10.1001/jamanetworkopen.2025.28585
- 2025
Circulating tumor DNA in biliary tract cancers: a review of current applications First author
Teixeira MF, Borad M, Uson Junior PLS. World Journal of Clinical Oncology. DOI 10.5306/wjco.v16.i10.107875
- 2025
Perioperative immunotherapy in gastric cancer in the spotlight
Pernomian LS, Teixeira MF, Araujo RLC, Uson Junior PLS. World Journal of Clinical Oncology. DOI 10.5306/wjco.v16.i12.110988
- 2025
Tumor-agnostic therapies in a high-volume Brazilian center: real-world challenges and opportunities First author
Teixeira MF, Lara Gismondi CBB, Zugman M, … Kaliks RA, et al. Journal of Clinical Oncology, 43(16_suppl):e23304. DOI 10.1200/JCO.2025.43.16_suppl.e23304
- 2025
Impact of chemoimmunotherapy vs chemotherapy alone in patients with HRD-positive and HRD-negative biliary tract cancers: a multicenter retrospective survival analysis
Abidoye O, Shibuki T, Pirozzi A, … Teixeira MF, et al. Annals of Oncology, 36:S130. DOI 10.1016/j.annonc.2025.05.347
- 2025
Time toxicity associated with first-line treatment in patients with advanced biliary tract cancer
Okano N, Pirozzi A, O’Donnell C, … Teixeira MF, et al. Annals of Oncology, 36:S128. DOI 10.1016/j.annonc.2025.05.343
- 2025
Impact of homologous recombination deficiency on response to chemoimmunotherapy in biliary tract cancer
Oluseyi A, Kosiorek H, Shibuki T, … Teixeira MF, et al. Journal for ImmunoTherapy of Cancer, 13(Suppl 2):A501.
- 2024
Molecular profile and actionability of sarcomas with next-generation sequencing: insights from a single institution in Brazil
Zugman M, Fernandes M, de Lima L, Teixeira MF, et al. ESMO Open, 9:133P.
Earlier publications, before oncology (7)
- 2021
Engagement with an asthma app to monitor medication adherence and its association with patients’ characteristics First author
Teixeira MF, et al. European Respiratory Journal. DOI 10.1183/13993003.congress-2021.OA3947
- 2021
Phenotypes of persistent asthma in adolescents revealed different patterns in longitudinal asthma-related outcomes First author
Teixeira MF, et al. European Respiratory Journal. DOI 10.1183/13993003.congress-2021.OA2566
- 2021
Determinants of the use of health and fitness mobile apps by patients with asthma: secondary analysis of observational studies
Neves AL, et al. Journal of Medical Internet Research. DOI 10.2196/25472
- 2021
Monitoring adherence to asthma inhalers using the InspirerMundi app: analysis of real-world, medium-term feasibility studies
Jácome C, et al. Frontiers in Medical Technology. DOI 10.3389/fmedt.2021.649506
- 2021
Feasibility and acceptability of an asthma app to monitor medication adherence: mixed methods study
Jácome C, et al. JMIR mHealth and uHealth. DOI 10.2196/26442
- 2020
Healing by second intention as a therapeutic alternative for serious blebitis
Barbosa JC, Silva SAR, Kanadani FN, … Teixeira MF, et al.
- 2019
Quality of life in systemic lupus women with cutaneous damage on the face: cosmetic camouflage impact
Lanna CC, Oliveira FAP, … Teixeira MF, et al. Annals of the Rheumatic Diseases, 78:1698.
Contact
Where to find me
Follow new articles and treatment updates on my social channels.
- Where to find me
- Hospital Israelita Albert Einstein, Medical Oncology team
Av. Albert Einstein, 627 · Morumbi, São Paulo, Brazil - Languages
- Portuguese, English and Spanish
- Medical license
- CRM-SP 220000 · CRM-MG 86471 · RQE 71154 (Medical Oncology)